Pharmidex Part of Consortium in New Innovate UK Grant
December 11, 2019

A Consortium led by Intract Pharma has successfully been awarded funding from Innovate UK to develop a scalable manufacturing process for novel oral antibody products using it's proprietary Soteria® technology. Pharmidex are also members of this consortium together with Centre for Process Innovation (CPI) and Quay Pharma.

Intract Pharma Ltd has successfully been awarded funding from Innovate UK, the UK’s innovation agency, to develop a scalable manufacturing process for novel oral antibody products using its proprietary Soteria® technology. The collaborative industrial research project, totalling over £1.4 million, was secured through the Industrial Strategy Challenge Fund for innovative projects in medicines manufacturing. This program will be conducted by a consortium led by Intract, including the Centre for Process Innovation (CPI), Pharmidex and Quay Pharma.


Each member of the consortium brings unique expertise in drug development and manufacture, with an extensive understanding of pharmaceutical formulation. The project seeks to develop a manufacturing process for Intract’s revolutionary Soteria® technology which can be scaled in a commercially viable manner. Soteria® transforms painful and inconvenient injectable therapies into safe, simple oral formulations, and allows targeting and concentration of the antibody at the site of disease in the gut to improve therapeutic efficacy whilst minimising risk of systemic toxicity.


About Pharmidex


Pharmidex provides translational solutions using its world-renowned expertise in CNS/Oncology, drug discovery and ADMET/PK. Founded in the UK in 2002, Pharmidex operates in state-of-the-art facilities in London and Hatfield to provide high quality bespoke experimental data to support drug discovery & development.


About Intract Pharma


Intract Pharma is an oral drug delivery specialist, developing state-of-the-art formulation technologies and unique gastrointestinal models to develop advanced new therapeutics. Since its inception, Intract has pursued innovation in oral drug delivery as a means to improve on current therapies, making them safer and more effective for patients. Soteria® is available for license exclusively from Intract Pharma. For more information visit www.intractpharma.com


About CPI


The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. The company uses applied knowledge in science and engineering combined with state-of-the-art development facilities to enable its clients to develop, prove, prototype and scale up the next generation of products and processes. Its open innovation model enables clients to develop products and prove processes with minimal risk. CPI provides assets and expertise, so customers can demonstrate processes before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale. By utilising its proven assets and expertise, companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and CPI’s technology transfer and engineering teams can help companies transfer the product or process into full-scale production at speed.


About Quay Pharma


Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials manufacturing for pharmaceutical and biotechnology companies worldwide. Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre-clinical through to the end of phase II clinical trials. Quay Pharmaceuticals has built a reputation for specialising in the formulation of APIs that exhibit poor solubility and bio-availability and those which require modified or controlled release.


About Innovate UK


Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org

January 8, 2026
We’re pleased to share that Martin Barrett from Pharmidex will be attending the R SC-BMCS Postgraduate Symposium XIX – Biological and Medicinal Chemistry Symposium for Postgraduates. ๐Ÿ“… Thursday 8th January 2026 ๐Ÿ“ MIB Building, Manchester Martin will be presenting at the symposium and representing Pharmidex to discuss our services and capabilities in drug discovery and development. He would be delighted to meet and chat with attendees, explore new ideas, and discuss potential collaborations and partnerships. If you’re attending, please come and say hello! ๐ŸŒ www.pharmidex.com ๐Ÿ”— https://www.rscbmcs.org/events/psxix/
January 5, 2026
We’re excited to expand our Bioanalytical team and are currently recruiting for two on-site, full-time roles supporting regulated and non-regulated programmes across small and large molecules: 1 - Technical Specialist, Bioanalysis (LC-MS) This is a senior technical authority role for an experienced LC-MS/MS scientist who enjoys solving complex analytical challenges and shaping technical direction. You’ll lead advanced method development and validation, support regulated studies, and mentor other scientists within a collaborative CRO environment. Ideal for candidates with: 5+ years of hands-on LC-MS/MS bioanalytical experience Strong expertise in method development, validation, and troubleshooting Experience with peptides, oligonucleotides, and large molecules Solid knowledge of GLP/GCP bioanalysis CRO experience (strongly preferred) 2 - Bioanalytical Scientist (Regulatory Studies) This role suits a hands-on bioanalytical scientist with experience delivering high-quality data for GLP/GCP studies. You’ll be involved across the full bioanalytical workflow, from method development to reporting, working closely with internal teams and (depending on experience) clients. Ideal for candidates with: A degree in Chemistry or a related discipline 5+ years’ experience in a bioanalytical laboratory Proven experience supporting GLP and/or GCP studies Strong LC-MS, sample preparation, and large-molecule expertise Experience with peptides and oligonucleotides โœจ Why Pharmidex? At Pharmidex, you’ll join a science-driven CRO where quality, accountability, and technical excellence matter. These roles offer real impact, strong collaboration, and the opportunity to contribute to diverse therapeutic programmes. ๐Ÿ“ฉ Interested? Please, check the full offers detail at https://www.pharmidex.com/careers-at-pharmidex and send your CV and a short cover note to [email protected] Feel free to share or tag anyone who might be a great fit!
December 31, 2025
As we step into 2026, we’re proud to continue supporting our clients with local UK expertise delivered at an international scale. At Pharmidex , we support programmes from discovery through to IND-enabling studies, helping teams progress confidently from concept to clinic. With integrated in vivo, bioanalysis and translational capabilities, everything is delivered under one roof in the UK, ensuring quality, continuity and efficiency at every stage. 2025 was one of the most challenging years our industry has faced, yet together we continued to deliver meaningful science, supporting nearly 1,000 projects and contributing to medicines that make a real difference to patients’ lives. Thank you to our clients and partners for your continued trust. We look forward to supporting innovation and high-quality science in the year ahead.
More Posts